The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
User Wonderful_Tonight910 suffered from hair loss and seborrheic dermatitis for years. After using irritant-free shampoo, their scalp improved, hair loss stopped, and new hair growth appeared.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
A user experienced a painful rash from both liquid and foam minoxidil, suggesting an allergy to minoxidil itself. They are seeking others with similar experiences.
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
Switching from liquid to foam minoxidil led to hair loss for OP, possibly due to a second shedding cycle. OP experienced allergic reactions to propylene glycol in the liquid form, causing dandruff and itchiness, which improved after switching to foam.
The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
The user is seeking recommendations for scalp-friendly minoxidil and RU58841 products available in the UK, as previous products caused scalp inflammation. They mention issues with RUDirect and MinoxidilMax products.
OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.
The user is considering using Minoxidil and Tretinoin to manage hair loss while waiting for Breezula/PP405, as they cannot tolerate dutasteride or finasteride. They hope these treatments will help retain hair despite ongoing loss.
The user shared progress pictures over four months using topical finasteride, topical and oral minoxidil, topical RU58841 daily, and oral dutasteride once a week. The pictures are spaced about a month apart.
How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.
The conversation discusses the effects of using Tongkat ali and dioscorea to raise DHT levels, leading to increased body hair growth and an itchy scalp, without causing hair loss. The discussion also debates the role of DHT in male characteristics and its impact on sexual function, with differing opinions on its importance and effects.
Sunburns on the scalp can cause permanent hair loss, especially for those using Tretinoin or Tacrolimus. Wearing UPF 50+ hats is recommended to protect against UV radiation.
The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.
A 22-year-old male using 0.5mg Dutasteride and 2.5mg oral Minoxidil daily for 5.5 months reports increased shedding and scalp itching. He also experienced acne and is concerned about whether the shedding is normal and if daily hair washing for seborrheic dermatitis is causing dryness.
The user is experiencing increased hair loss and was diagnosed with male pattern baldness. They are considering using oral or topical finasteride to manage the condition and are contemplating cutting their hair short.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.
The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.